Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab use in hospitalized patients with emerging or reemerging acute respiratory infectious diseases and hypercholesterolemia
ChiCTR2600132712Phase 4Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of evolocumab in acute respiratory illness (ARI), emerging infectious diseases (EID), reemerging infectious disease (REID) and 1 more (2 arms), sponsored by Shanghai General Hospital. Primary endpoints: Time from study inclusion to clinical recovery in the mild illness subgroup and 28-day all-cause mortality in the severe illness subgroup. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
evolocumab
03
Conditions
acute respiratory illness (ARI)emerging infectious diseases (EID)reemerging infectious disease (REID)hypercholesterolemia
Beyond the preview
Go deeper on ChiCTR2600132712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132712.